Journal
ANNALS OF ONCOLOGY
Volume 21, Issue 5, Pages 1064-1071Publisher
ELSEVIER
DOI: 10.1093/annonc/mdp425
Keywords
chemotherapy; CHOP; dose intensity; doxorubicin; non-Hodgkin's lymphoma
Categories
Ask authors/readers for more resources
Methods: A Medline and Cochrane library search was carried out using the search terms 'CHOP', 'lymphoma' and 'randomized trials'. Eligible trials had CHOP as a control arm and any regimen administering doxorubicin at a higher DI (16.6 mg/m(2)/week) as the investigational arm. Pooling of data was carried out using the mixed effect model. Results: Eight trials were eligible. Patients receiving DI doxorubicin-based regimens had a significantly better overall survival [summary hazard ratio (SHR) 0.82; 95% confidence interval (CI) 0.71-0.96], event-free survival (SHR 0.86; 95% CI 0.75-0.99) and higher complete response rate (summary odds ratio 0.91; 95% CI 0.67-0.97). Conclusion: High DI doxorubicin based should be considered in patients with aggressive NHL.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available